What is HC Wainwright’s Forecast for Evolus FY2025 Earnings?

Evolus, Inc. (NASDAQ:EOLS) – Equities researchers at HC Wainwright dropped their FY2025 earnings per share estimates for Evolus in a research report issued to clients and investors on Wednesday, March 5th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.23) per share for the year, down from their prior estimate of $0.11. HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Evolus’ FY2026 earnings at $0.49 EPS, FY2027 earnings at $1.16 EPS, FY2028 earnings at $2.35 EPS and FY2029 earnings at $3.81 EPS.

Several other brokerages also recently weighed in on EOLS. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Evolus in a report on Wednesday, March 5th. Barclays increased their price objective on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th.

Evolus Trading Up 0.6 %

Shares of NASDAQ EOLS opened at $13.58 on Monday. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The business’s 50 day moving average price is $12.95 and its 200-day moving average price is $14.05. Evolus has a fifty-two week low of $9.25 and a fifty-two week high of $17.82. The company has a market cap of $863.51 million, a price-to-earnings ratio of -14.92 and a beta of 1.28.

Institutional Trading of Evolus

A number of institutional investors have recently made changes to their positions in EOLS. KBC Group NV acquired a new stake in shares of Evolus in the 4th quarter worth $49,000. IFP Advisors Inc boosted its position in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after purchasing an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Evolus in the 4th quarter worth $106,000. Rafferty Asset Management LLC acquired a new stake in shares of Evolus in the 4th quarter worth $115,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Evolus in the 4th quarter worth $118,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.